New drug combo aims to shrink aggressive prostate tumors before surgery

NCT ID NCT00329043

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding the drug sunitinib to standard hormone therapy can shrink or control high-risk prostate cancer before the prostate is removed. About 64 men with localized but aggressive prostate cancer will receive sunitinib pills plus a hormone blocker for up to 3 months, then undergo surgery. The main goal is to see if the cancer completely disappears in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sunitinib malate (Sutent) plus a hormone blocker (LHRH agonist like Lupron)
What this could lead to: If it works, this combination could help shrink aggressive prostate tumors before surgery, potentially lowering the risk of cancer coming back.
What could go wrong: This is a small, early-phase trial (64 people) with no control group, so results may not apply broadly. Sunitinib can cause side effects like fatigue, high blood pressure, and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.